Diagnosis and treatment of osteoporosis in childhood;Diagnóstico e terapêutica da osteoporose na idade pediátrica

Acta Medica Portuguesa

Volumn 17, Issue 5, 2004, Pages 385-390

  Canhão, Helena ^a   Fonseca, João Eurico ^a   Queiroz, M Viana ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Children; Densitometry; Diagnosis; Osteoporosis; Therapy

Indexed keywords

CALCITONIN; VITAMIN D;

AGE DISTRIBUTION; BONE MASS; CHILDHOOD DISEASE; DENSITOMETRY; HUMAN; OSTEOPOROSIS; QUANTITATIVE ANALYSIS; REVIEW; TREATMENT OUTCOME;

BONE DENSITY; CHILD; HUMANS; OSTEOPOROSIS;

EID: 14644392796     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Osteoporosis prevention, diagnosis and therapy: NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. JAMA 2001; 285(6): 785-95
2. Consensus Development Conference: Diagnosis, prophylaxis and treatment of Osteoporosis. Am J Med 1993; 94: 646-50
3. SILVEIRA A, LOPES NC: Fracturas proximais do femur no idoso. Influência de um protocolo de cirurgia imediata e reabilitaç áo em ambulatório na morbilidade e mortalidade. Rev Port Ortop Traum 1997; 5: 27-33
4. CENTER JR, NGUYEN TV, SCHNEIDER D et al: Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353: 878-82
5. POOR G, ATKINSON EJ, O'FALLON WM, MELTON LJ III: Determinants of reduced survival following hip fractures in men. Clin Orthop 1995; 319: 260-5
6. BROWNER WS, PRESSMAN AR, NEVITT MC, CUMMINGS SR: Mortality following fractures in older women: the study of osteoporotic fractures. Arch Intern Med 1996; 156: 1521-5
7. TAVARES V, MATOS ACA, BRANCO JC et al: Mortalidade e custos hospitalares das fracturas da anca. Acta Reuma Port 1990; 15(supl 1): 66
8. KANIS JA, MELTON LJ III, CHRISTIANSEN C et al: The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137-41
9. KANIS JA: Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359: 1929-36
10. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Tecnical report series 843. Geneva, WHO, 1994
11. BONJOUR JP: Bone mineral acquisition in adolescence. In Osteoporosis. Edited by Marcus R, Feldman D, Kelsey J. San Diego. Academic Press 1996: 465-76
12. WAHNER HW, FOGELMAN I: Bone mineral measurements in the growing skeleton. In The evaluation of osteoporosis: Dual energy X-ray absorptiometry in clinical practice. Ed Martin Dunitz. London 1994 pp 219-229
13. WAHNER HW, FOGELMAN I: Measurement of bone mineral in the lumbar spine: the AP spine scan. In The evaluation of osteoporosis: Dual energy X-ray absorptiometry in clinical practice. Ed Martin Dunitz. London 1994 pp 88-120
14. MILLER PD, BONNICK SL, ROSEN CJ: Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population. Calcif Tissue Int 1996; 58: 207-14
15. DEAL CL: Using bone densitometry to monitor therapy in treating osteoporosis: pros and cons. Curr Rheumatol Rep 2001; 3 (3): 233-9
16. CUMMINGS SR, PALERMO L, BROWNER H, et al: Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 2000; 283(10): 1318-21
17. CUMMINGS SR, PARFITT AM: Bone density regression to the mean and the individual patient. J Clin Endocrinol Metab 2001; 86(8): 4001-2
18. KANIS JA: Treatment of symptomatic osteoporosis with fluoride. Am J Med 1993; 95(5A): 53S-61S
19. MOSEKILDE L: Vertebral structure and strenght in vivo and in vitro. Calcified Tissue Int 1993; 53(Suppl 1): S121-S126
20. CHESNUT CH 3rd, ROSE CJ: Bone Quality Discussion Group. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fractures. JBMR 2001; 16: 2163-72
21. In Bone Markers: biochemical and clinical perspectives. Ed Eastell R, Baumann M, Hoyle NR, Wieczorek L. Martin Dunitz. London 2001
22. CLEMENS JD, HERRICK MV, SINGER FR, EYRE DR: Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clinical Chemistry 1997; 43: 2058-63
23. GARNERO P, MULLEMAN D, MUNOZ F, SORNAY-RENDU E, DELMAS PD: Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study. J Bone Miner Res 2003; 18(10): 1789-94
24. ASTROM E, SODERHALL S: Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child. 2002; 86(5): 356-64
25. ROUX S, ORCEL P: Bone loss. Factors that regulate osteoclast differentiation: an update. Arthritis Res. 2000; 2(6): 451-456
26. SAIDENBERG-KERMANAC'H N, CORRADO A, BESSIS N, DE VERNEJOUL M-C, BOISSIER M-C, COHEN-SOLAL M: TNF-alpha Antibodies and OPG Decrease Bone Loss Associated Inflammation Through Distinct Mechanisms in Collagen Induced Arthritis. Arthritis Rheum 2003; Suppl 1, vol 48: S148
27. NIH Consensus conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA 1994; 272(24): 1942-8
28. CHESNUT CH 3, SILVERMAN S, ANDRIANO K, et al: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000; 109(4): 267-76
29. CIMAZ R: Biphosphonates in the pediatric rheumatic diseases. Pediatric Rheumatol Online J 2003; 1(2): 29-33
30. GLORIEUX FH, BISHOP NJ, PLOTKIN H, CHABOT G, LANGUE G, TRAVERS R: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339(14): 947-52
31. RAUCH F, PLOTKIN H, ZEITLIN L, GLORIEUX FH: Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003; 18(4): 610-4
32. ZEITLIN L, RAUCH F, PLOTKIN H, GLORIEUX FH: Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003; 111(5 Pt 1): 1030-6
33. LANDSMEER-BEKER EA, MASSA GG, MAASWINKELMOOY PD, VAN DE KAMP JJ, PAPAPOULOS SE: Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr. 199; 156(10): 792-4
34. NOGUERA A, ROS JB, PAVIA C, ALCOVER E, et al: Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. J Pediatr Endocrinol Metab 2003; 16(4): 529-36
35. ALLGROVE J: Use of bisphosphonates in children and adolescents. Pediatr Endocrinol Metab. 2002; 15(Suppl 3): 921-8
36. BIANCHI ML, CIMAZ R, BARDARE M, et al: Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000; 43(9): 1960-6
37. DEQUEKER J, DECLERCK K: Fluor in the Treatment of Osteoporosis: An overview of thirty years clinical research. Schweiz Med Wochenschr 1993; 123(47): 2228-34
38. BALENA R, KLEEREKOPER M, FOLDES JA, et al: Effects of different regimens of sodium fluoride treatment for osteoporosis on the structure, remodeling and mineralization of bone. Osteoporos Int. 1998; 8(5): 428-35
39. MARINI JC, HOPKINS E, GLORIEUX FH, et al: Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen J Bone Miner Res. 2003; 18(2): 237-43
40. SIMON D, LUCIDARME N, PRIEUR AM, RUIZ JC, CZERNICHOW P: Effects on growth and body composition of growth hormone treatment in children with juvenile idiopathic arthritis requiring steroid therapy. J Rheumatol 2003; 30(11): 2492-9
41. NEER RM, ARNAUD CD, ZANCHETTA JR, et al: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344 (19): 1434-41
42. REGINSTER JY, MEUNIER PJ: Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporos Int. 2003; 14 Suppl 3: S56-65